Small nuclear ribonucleoprotein Sm D3 (SNRPD3)

Small nuclear ribonucleoprotein Sm D3 (SNRPD3) is a highly conserved, essential core component of the spliceosome, responsible for pre-mRNA splicing in eukaryotic cells[5][6][3][7]. SNRPD3 is one of seven Sm proteins that form a heptameric ring structure critical for spliceosome assembly, stability, and nuclear import[1][8]. It is symmetrically dimethylated by PRMT5, a modification important for proper spliceosomal function[1]. SNRPD3 regulates alternative splicing in both physiological and cancer contexts, ensuring transcript fidelity and influencing cell proliferation and survival—especially in oncogenic environments, such as MYCN-driven neuroblastoma[1][2][8]. It is also recognized as a key autoantigen, forming epitopes targeted by anti-Sm antibodies in systemic lupus erythematosus[2][6]. While not a classical drug target, SNRPD3 has gained attention as a cancer-selective lethal target and as a diagnostic marker in autoimmune disease. Therapeutic approaches exploiting SNRPD3’s splicing function or post-translational modification are actively being investigated, alongside its potential risks for toxicity in normal cells[1][2][8].

Other names

Small nuclear ribonucleoprotein D3 polypeptideSNRPD3Sm-D3SMD3snRNP core protein D3small nuclear ribonucleoprotein Sm D3, 18kDaU1/U2/U4/U5 snRNP protein D3[3][5][6][2]

Potential mechanisms involve: Inhibition of SNRPD3 expression or function, leading to cytotoxic splicing errors in cancer cells[1][2][8]. Interference with SNRPD3 methylation by PRMT5 to selectively impair survival of malignant cells[1][2]. Targeting SNRPD3 autoepitopes for diagnostic purposes in SLE[2]. No approved or well-characterized drugs act directly on SNRPD3 via a classical "drug-target" relationship[2][8].